Articles On Immutep (ASX:IMM)

Immutep (ASX:IMM), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, has announced the Chinese Patent Office has awarded a new patient for eftilagimod alpha.

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

The Immutep Ltd (ASX: IMM) share price finished strongly today. This came after the company announced it has been granted a new Chinese patent. At close of trading today, the biotechnology company’s shares were trading at 67 cents, up 13.5...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Biotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gains in May which has seen its share price rise by almost 500 per cent over the past 12 months. Each week, Stockhead recaps ASX stocks that are...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco...

Summary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of the 11 sectors traded in the green, while tech stocks lead the pack with a 4.32% gain.  Afterpay emerges as the top gainer, followed by Redbu...

Summary The ASX 200 is heading towards its worst performance since late February, down 2% at 6924.10 at the close. The market breadth was extremely week, with all the 11 sectoral indices trading in red. EML Payments shares plunged ove...

Summary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead programs in the US and Japan, respectively. Paradigm Biopharmaceuticals has received first revenue through a physician prescription of Zilosul®....

Cancer immunotherapy developer Immutep Ltd [ASX:IMM] share price is trading neutral at time of writing, holding steady after flip-flopping between earlier gains and losses... The post Immutep Shares Hold Steady despite Operational Update (A...

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

ShareCafeImmutep: A leader in a league alongside global Pharma giants Immutep (IMM.ASX) is one of the most promising drug developers listed on the ASX. The company’s lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), which is...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

The Immutep Ltd [ASX:IMM] share price is up 11.4% today after securing fast track designation from the US FDA for its eftilagimod alpha product. IMM shares were up as much as 17% in early trade... The post Immutep Share Price Soars on US F...

08 April 2021 - Biotechnology company Immutep (ASX:IMM) has received a fast-track approval from the United States Food and Drug Administration (FDA) for its lead product ‘efti’.

Immutep (ASX:IMM) shares have hit their highest level in early trade after the Sydney biotech company’s lead product candidate was green-lit for possible early regulatory approval in the United States. Immutep’s drug candidate eftilagimod a...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on form again and charging higher. At the time of writing, the benchmark index is up 1.1% to 7,006.3 points. Four ASX shares that are climbing more than most today are listed be...

Source:Khakimullin, Shutterstock Summary The ASX 200 on Thursday opened higher, up 13.70 points, or 0.20%, to 6,941.70, even as the US stock markets closed mixed overnight.   Metals & Mining and Resources were up by over 1%...

The Immutep Ltd (ASX: IMM) share price has been a strong performer again on Thursday. In morning trade, the biotechnology company’s shares are storming 10% higher to 48.5 cents. Why is the Immutep share price storming higher? Investors hav...

Immutep (ASX:IMM) has announced that the US FDA has granted fast-designation to its lead product candidate eftilagimod alpha.

S&P 500 at record high again, after release of Fed minutes S&P 500 has set a record high again, marking the 18th time it has done so this year. The index rose by 0.15%, after the Fed said it will continue ultra-low interest rates po...

Source:elwynn, Shutterstock Summary Nexion Group Ltd (ASX:NNG) on Thursday announced that it had completed agreement to acquire Blue Sky Telecom Pty Ltd as part of its growth strategy. The agreement to acquire 100 per cent of the issu...

Source:Khakimullin , Shutterstock Summary Immutep Ltd (ASX:IMM) announced that its lead product candidate eftilagimod alpha or efti had received fast track designation from the United States Food and Drug Administration (FDA). Efti ha...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. At the time of writing, the biotechnology company’s shares are swapping hands for 44 cents, up 2.35%. What was announced...

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

Wall Street slides, as IMF raises global growth forecast All major US indices slid on Tuesday, but stayed near record highs gained the previous day. Dow Jones closed 0.29% lower, S&P500 dropped 0.1%, while tech heavy NASDAQ slid 0.05%....

Australian company Immutep (ASX:IMM) says positive trial results from a new combination including Bristol Myers Squibb's PBS-listed OPDIVO (nivolumab) highlights the potential of its own lead candidate.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is tumbling lower. At the time of writing, the benchmark index is down 0.2% to 6,812.2 points. Four ASX shares that are falling more than most to...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

Source:ShutterstockProfessional, Shutterstock Summary Lefroy Exploration has been making the headlines since the last month. The stock has shot up by over 63 per cent to A$1.125. Digital Wine Ventures has signed a memorandum of unders...

The best performer on the All Ordinaries index on Friday by some distance has been the Immutep Ltd (ASX: IMM) share price. In afternoon trade, the biotechnology company’s shares are up 29% to 44.5 cents. At one stage today, the Immutep sha...

Immutep (ASX:IMM) shares have spiked after Bristol Myers Squibb announced that a drug similar to Immutep’s lead candidate had succeeded in fighting cancer in a large study. Patients treated with Bristol Myer Squibb’s anti-LAG-3 monoclonal a...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Immutep (ASX:IMM) shares closed 10.5 per cent higher on Tuesday after the Sydney biotech announced it would collaborate with drug giant Merck & Co on another clinical trial. The two companies will hold a Phase IIb trial evaluating how t...

Source: CI Photos, Shutterstock Summary ASX-listed leading immunotherapy developer Immutep Limited entered into a second clinical trial collaboration with Merck & Co’s subsidiaries. Diagnostic company BARD1 Life Sciences revealed...

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology...

Immutep (ASX:IMM), an Australian biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, has announced a second clinical trial collaboration and supply agreement with MS...

Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents. Immute...

The Immutep Ltd (ASX: IMM) share price is down 1.59% at the time of writing trading at 31 cents a share. This follows this morning’s announcement that Immutep is expanding Part B of its cancer treatment clinical trial. Let’s break down wha...

Summary Respiri Limited announced that Pharmacy Catalyst members to provide support to sales of wheezo with the in-pharmacy asthma management program. The Company would continue to introduce the program across several other members pha...

When it comes to biotech stocks, few are as ambitious as Immutep Ltd [ASX:IMM]. Because when they’re not battling to try and treat cancer, they’re busy trying to stave off COVID-19. Which is exactly what has sent the IMM share price climbin...

Immutep (ASX:IMM) shares are up nearly five per cent this morning after the Sydney biotech said a trial of its ... Read More The post Immutep Covid-19 trial moves forward in Czech Republic appeared first on Stockhead.

Summary Global biotech company Immutep announces the advancement in Phase 2 trial assessing eftilagimod alpha in COVID-19 patients. The Company said that positive recommendation from the DSMB builds on strong safety profile for eftilag...

A trial of biotechnology company Immutep's (ASX: IMM) experimental cancer drug on COVID-19 patients will go ahead, after a preliminary test found the immune boosting drug was safe for use. As a result Immutep will see the trial progress t...

Summary Active biotechnology player Immutep has completed enrolment and dosing for the last patient in the TACTI-002 trial. The Company expects further data from the study in the first half of 2021. Immutep has also commenced the enro...